Jump to content

Alison Todd

From Wikipedia, the free encyclopedia

Alison Todd
Alma materUniversity of Sydney
(BSc)
Royal Prince Alfred Hospital (PhD)
Scientific career
InstitutionsJohnson and Johnson
SpeeDx
Thesis Molecular analysis of regulatory and transforming sequences of the human N-ras gene[1]

Professor Alison Todd FTSE is holder of 18 patents (as at July 2019),[2] and a co-founder and chief scientific officer of SpeeDx.[3] The company manufactures and sells tests for detecting infectious pathogens and identifying antibiotic resistance.[4] The biomedical company, co-founded by Todd, develops diagnostic tools.[5] Todd mentors younger scientists and entrepreneurs, as well as advocating for greater gender diversity in leaders in STEM.[6] ‘Nearly 60 per cent of medical science and health graduates are women, but we hold only 20 per cent of senior leadership positions in the field’.[6]

Career

[edit]

Todd is the Chief Scientific Officer of SpeeDx, which is a molecular diagnostics company which she and Elisa Mokany started. Todd and Mokany have 18 patent families between them. They have brought 11 medical diagnostic tests for the management of clinical disease.[3]

Todd developed several novel molecular analytical technologies which have been used for basic research, preclinical/clinical drug development and in vitro diagnostics. Her expertise include nucleic acid chemistry, particularly target amplification and catalytic DNA technologies, and the biology of cancer and viral diseases. Prior to founding SpeeDx, Todd was a Senior Research Director at Johnson and Johnson Research Pty Limited, Sydney.[citation needed]

Todd describes her work, "We are proud of what we have created because we believe we are making a positive contribution to the welfare of patients around the world. As the old-timer of the pair, I will take the liberty of having the last word and sum up our relationship as a clear case of ‘two heads are better than one’.[7]

Research

[edit]

Todd describes her "Eureka moment", "It all began when Elisa joined my group at Johnson & Johnson Research (JJR), we were already exploring ways to exploit DNAzymes (deoxyribozymes) for diagnostic applications. These fascinating molecules are simple, short, synthetic DNA sequences (oligonucleotides) that can catalyse reactions in a manner analogous to protein enzymes. Although catalytic RNA (ribozymes) had been found in nature, catalytic DNA had not, and it had been assumed DNA would not have similar properties. However, a few years earlier, undeterred by dogma, Jerry Joyce and co-workers at Scripps had conducted ‘evolution in a test tube’".[7]

Select publications

[edit]
  • Santoro, S., and Joyce, G. (1997) A general purpose RNA-cleaving SNA enzyne. Proc. Natl. Acad. Sci. USA 94, 4262-4266.[8]
  • Todd, A.V., et al. (2000) DzyNA-PCR: use of DNAzymes to detect and quantify nucleic acid sequences in a real-time fluorescent format Clin. Chem. 46, 625-630.[9]
  • Mokany, E., et al. (2010) MNAzymes, a Versatile New Class of Nucleic Acid Enzymes That Can Function as Biosensors and Molecular Switches J. Am. Chem. Soc. 132, 1051-1059.[10]
  • Mokany, E., et al. (2013) MNAzyme qPCR with Superior Multiplexing Capacity Clin. Chem. 59, 419-426.[11]

Todd's publications can be found at (Google Scholar).[12]

Awards and recognition

[edit]
  • Todd was awarded the Johnson & Johnson Philip B. Hofmann Research Scientist Award, an international award recognising outstanding achievement in research and development.[13]
  • Todd was selected as one of the six Boss True Leaders Game Changers due to her research fighting superbugs.[6]
  • In 2019 Todd was elected Fellow of the Australian Academy of Technological Sciences and Engineering (FTSE).[14]

Media

[edit]

2017 — Todd's work was referenced in The Australian Financial Review, where she was described as a 'frontline fighter in the war on superbugs'.[15]

2017 — An article from Australian Biochemist describes in technical detail, the complexity, yet elegant simplicity that Todd's company uses technology to test infectious diseases.[7]

2017 — The Sydney Morning Herald described the formation of Todd's company, as well as their concern that women were under-represented in STEMM, and the hiring and mentoring practices reflected in their company.[16]

References

[edit]
  1. ^ Todd, Alison Velyian (1992), Molecular analysis of regulatory and transforming sequences of the human N-ras gene
  2. ^ "News - Brisbane Girls Grammar School". www.bggs.qld.edu.au. Retrieved 2 August 2019.
  3. ^ a b "SpeeDx | Executive Team". SpeeDx. Archived from the original on 19 July 2019. Retrieved 27 July 2019.
  4. ^ "True Leaders Game Changers 2017: SpeeDx's Alison Todd frontline fighter in the war on superbugs". Australian Financial Review. 12 October 2017. Retrieved 27 July 2019.
  5. ^ Commission, Australian Trade and Investment. "Australian startup wages war on drug-resistant sup". www.austrade.gov.au. Retrieved 27 July 2019.
  6. ^ a b c "Dr Alison Todd returns to Girls Grammar to share her passion for entrepreneurship - Brisbane Girls Grammar School". www.bggs.qld.edu.au. Retrieved 2 August 2019.
  7. ^ a b c "Australian Biochemist" (PDF). 25 July 2019. Archived from the original (PDF) on 20 October 2022.
  8. ^ Santoro, S. W.; Joyce, G. F. (29 April 1997). "A general purpose RNA-cleaving DNA enzyme". Proceedings of the National Academy of Sciences of the United States of America. 94 (9): 4262–4266. Bibcode:1997PNAS...94.4262S. doi:10.1073/pnas.94.9.4262. ISSN 0027-8424. PMC 20710. PMID 9113977.
  9. ^ Todd, A. V.; Fuery, C. J.; Impey, H. L.; Applegate, T. L.; Haughton, M. A. (May 2000). "DzyNA-PCR: use of DNAzymes to detect and quantify nucleic acid sequences in a real-time fluorescent format". Clinical Chemistry. 46 (5): 625–630. doi:10.1093/clinchem/46.5.625. ISSN 0009-9147. PMID 10794743.
  10. ^ Mokany, Elisa; Bone, Simon M.; Young, Paul E.; Doan, Tram B.; Todd, Alison V. (27 January 2010). "MNAzymes, a Versatile New Class of Nucleic Acid Enzymes That Can Function as Biosensors and Molecular Switches". Journal of the American Chemical Society. 132 (3): 1051–1059. doi:10.1021/ja9076777. ISSN 0002-7863. PMC 2808728. PMID 20038095.
  11. ^ Todd, Alison V.; Fuery, Caroline J.; Bone, Simon M.; Tan, Yee Lee; Mokany, Elisa (1 February 2013). "MNAzyme qPCR with Superior Multiplexing Capacity". Clinical Chemistry. 59 (2): 419–426. doi:10.1373/clinchem.2012.192930. ISSN 0009-9147. PMID 23232065.
  12. ^ "Alison Todd — Google Scholar Citations". scholar.google.com. Retrieved 27 July 2019.
  13. ^ "SpeeDx | Executive Team". SpeeDx. Archived from the original on 19 July 2019. Retrieved 28 July 2019.
  14. ^ "Dr Alison Todd – Molecular inventor". Applied. Retrieved 24 October 2019.
  15. ^ "True Leaders Game Changers 2017: SpeeDx's Alison Todd frontline fighter in the war on superbugs". Australian Financial Review. 12 October 2017. Retrieved 27 July 2019.
  16. ^ Khadem, Nassim (27 November 2017). "Aussie company SpeeDx is fighting a sexually transmitted infection that's acting like a superbug". The Sydney Morning Herald. Retrieved 27 July 2019.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Alison_Todd&oldid=1222161787"